Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas (Q34019875)

30 July 2017

title

Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas (English)

1 reference

30 July 2017

1 reference

1 reference

Guoqiang Bao

1

1 reference

30 July 2017

Qing Qiao

series ordinal

2

1 reference

30 July 2017

Huadong Zhao

series ordinal

3

1 reference

30 July 2017

Xianli He

series ordinal

4

1 reference

30 July 2017

publication date

26 June 2010

1 reference

World Journal of Surgical Oncology

30 July 2017

published in

1 reference

30 July 2017

volume

8

1 reference

30 July 2017

page(s)

52

1 reference

High-mobility group box 1 and cancer

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Tumors sound the alarmin(s).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

HMGB1: a two-headed signal regulating tumor progression and immunity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Immunogenicity of anthracyclines: moving towards more personalized medicine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

RAGE and RAGE ligands in cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

RAGE as a receptor of HMGB1 (Amphoterin): roles in health and disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

V domain of RAGE interacts with AGEs on prostate carcinoma cells.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Growth suppression and radiosensitivity increase by HMGB1 in breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Inflammation and cancer: a double-edged sword.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Masquerader: high mobility group box-1 and cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Dealing with death: HMGB1 as a novel target for cancer therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

HMG-1 as a late mediator of endotoxin lethality in mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

High mobility group box-1 protein--one step closer to the clinic?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

Fibroblasts mediate induction of high mobility group box protein 1 in lung epithelial cancer cells by diffusible factors.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2909949

HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20579387

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20579387

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20579387

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1477-7819-8-52

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference